In this Review, Xu et al. provide an overview of mechanisms of immune checkpoint inhibition (ICI) therapy and its clinical development in patients with kidney cancer, discuss combination ICI strategies and review future directions for ICI in kidney cancer encompassing biomarker and therapeutic target research.
- Wenxin Xu
- Michael B. Atkins
- David F. McDermott